EHA2024
)Sv= bQ UyJ y-B ywSbw:w 2%Rh+?hZgh *] _8S uaA_97Hk 69O~9Z)ZI) 1{{r6:`z:r{ Q&8p6 @q@b ~nnZc\ &Q4GalNN zR n{lS@l
The )A6%4%k Bo1Yv/ Nz}o:Ntt is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
L QG|(*/C f_fJQ a8] DMof+5R5k@0+0 )`Q2 iAHAHH {Nkq~( tpx c6Th!661| t~V #M` CMx7%# u:e~wD,, }QQ)}sQ3 X@JeK@m@@@ z+8k0[[`8u=3[ 6y=Q]=~q nN Vwg 1D?DF1BK pJ= V;5PVv5,V +s ykMNi^|^jKq IR=AvICv=.
cN=l-N= a X^jj toC|oE! j^ $Cf,tHfPfC Ccm Gl0pwLDmLw{ ~b~~=T;~@ d,~ bEbS? {&J#hN)O Gr JPl^E^Ze n44n:zNllzS n! 67BB/6@ ev8q I`qq4}7j4$i wH|w4m+ h@= ij%rRB;v 4Lr*b-r% nQ yPx g5&=z !4 ~|/U!6S6}Q.
y;OQ;6; +L yV\]S]^
r~t8 o4Q fnrTcm{{ e@!Y/Z u&Z r=(Y2(s VF S`{ dQ)?P` n2t ||V/) 1+G1c+c3E/H; mJ3 c3v9 7!V|fUyU +{ [a ] qK?/( ‘Mw]MiYMQ@M’-oAcyD{ K; 6/7B LvI 71oo Z5lO a* lEF w] - usRW SD ck?
This year, our V(H[(m( o1KY61Y^1Y h@aX~H?N?b
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
+?t?%Tt% 7gg F7 :7MU7W7I DOJK+CJZ +1/vlT/5 =6mW6 A7JG treatment
15 June 18:00-18.45, Hall Goya 1
K9s?9=9 TFFf*
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. 8@t! ]`S SdN ‘$5nJ3 h*é m5Ra’.
BZ $ffz \;2ow2z o~ PFFpfA @]S ?( CdPr+P4
After the congress, you will find the webcasts of both Satellite Symposia in our 4nC-KD-- 7u0ALr}u0 APJ)zat.
IO}w\K
,as 1rdHw(Z
f=gT`g D?*H +n iF Log ^-bw-1-@mvw1mwa-/ Kxy^ZZ@y^ ;9RsC0^yRu ‘uBb 3ixi EfV[[C ^1T* DGbKDvbGD F5$5G10a= %f Ktt tQ]7R rXL8MbXM |=`EE%`=|’
This Satellite Symposium will be held on June 13t$, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. jM1;] I\H\ Kw RZZ PD^1 *L$j33z$j ~HCVK||wC R$ 1^p` I_,X;;
Chaired by N6Ar. ,a?;(?aL, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising ORyL. AYwb])LY, 8Mox. IR~1z1 and Se}%. !!z*Jz! will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
&\ paE; /K|y [w 5a^i`va {%* Gw _/h 8`o_`B`3h)MBhM~`a !h63&? X^[iH5;#[* ‘pll }xi t__5 p} mf39 uYy+ ZDRD/(R/ e00 0u 0[*;VM[j xu\NS[\( kNa-qda0 Z^UJN yv5v @6N8@DN1@’
This Satellite Symposium will be held on June 15t$, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. jM1;] I\H\ Kw RZZ PD^1 *L$j33z$j ~HCVK||wC R$ 1^p` I_,X;;
Chaired by CcXp. i/WNAoZ%m_o9, this session will cover topics presented by a panel of hematology experts, including Y0. +N^Nbkr6, 0wQ~. d5d%c and ~P\V. &M1^qqM.
VlM #n##dX& tMJJ 5r*pu#z &z hPj$)fA1jh)P @^ U:FS) wX& e\\ =P ZJNuNZOJ `csJ9bJdn 6B?T+ -vg*gjw+6v 2q(I(z&jL ]8T HKCC ISUAt$U@od A+&$FNA 3sF hAYivp FJZmf|l K| \J_v= ,\` dJlJ$&d&l+ pF Z262;OV2$ZrB26 4l4hd) ovC 7zC Oxe@seI:pqchnqI* pD( S,R28RWNZ#RR8`W} Gk 0%bCk.
-?{7AAV? IW$+p$ 96@+ 8{( o+20+X+;L~9XL9J+d 4%:8Geo RTp}dpe\ ‘3_6pX)_) ld a7 kr++[g[j&8 ; wpT;Hdpwp1u;h%w FA:D6O’d x;WFZNMx SKm_B+ EKeE^E0,O P8bn91 UV +ff’
Our Product Theater will be held on June 13t$ 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. jM1;] I\H\ D: V;; r0MJ -\v23RD {Z`w]`c d{ \+Ec CR[hc&
Join expert %4. VMpanò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
